Business Wire

THE-BRAIN-FORUM

7.4.2016 11:11:51 CEST | Business Wire | Press release

Share
Lausanne to Be the Epicentre of Brain Research in May 2016

The Brain Forum brings together top scientists and entrepreneurs from the world’s biggest brain initiatives. The event will run in collaboration with EPFL on 26 and 27 May at the SwissTech Convention Center in Lausanne, Switzerland.

Launched in 2013, The Brain Forum plays an important role in the progression of brain research by connecting researchers, engineers, healthcare professionals, entrepreneurs, investors, funding agencies and policy makers. In so doing, The Brain Forum helps to accelerate our understanding of the brain by translating science from bench to business, thus making laboratory innovations available to all.

Dr. Jamil El-Imad, CEO of The Brain Forum, comments: “We want to include anyone with an interest in the brain. We hope that our different but complementary experience and perspectives can help to overcome the biggest challenges of this era. You can’t build the future based on present assumptions so we need to develop our thinking and be open to spontaneous opportunities that may lead to the necessary serendipity for innovation.”

The Brain Forum has proven a great success in previous years. This year the main objectives are to enhance the attendance of the international community, to promote awareness of brain science at a global level and to stimulate worldwide, unified efforts to tackle one of the biggest healthcare challenges of this century. The event features an impressive line-up of world-renowned experts who promise to give fascinating insights into cutting-edge research, advancements in our understanding of the brain and the impact of that knowledge. International brain initiatives and regulatory bodies from the EU, USA, Japan and China will share how they are working towards improving brain research. Google will host a special session on ‘Lessons from practical machine intelligence’ followed by UBS on ‘The Workforce of the Future,’ while the popular start-up competition returns offering opportunities for start-ups to pitch to investors looking to invest in the solutions of the future.

The Brain Forum was created because scientific exploration of the brain is fundamental for tackling the challenges of the 21st century. As more and more people are affected by neurological and psychiatric conditions, there is increasing awareness of the importance of brain research to healthcare and technology. WHO recently concluded that brain disorders account for 35 per cent of the burden of all diseases in Europe and will become the major medical need of this century. In 2010, the European Brain Council published a report demonstrating that brain disorders cost Europe EUR 800 billion in 2010 – more than cardiovascular disease, cancer and diabetes combined.

Dr. El-Imad adds: “The future is both terrific and terrifying. Our aging populations are increasing the incidence and burden of many neurological and psychiatric diseases presenting huge challenges for healthcare and society, while artificial intelligence will presage a new industrial revolution, altering the workforce of the future and shifting further the balance of humans vs. machines. Technology and science will allow us to do things that we never imagined possible, but we as a society need to be prepared to deal with the consequences – good and bad – of our rapidly changing future.”

To participate - and mould the future of brain science – register at:
www.thebrainforum.org

*Source: ME NewsWire

Contact:

Headline office
The Brain Forum
Christophe Tournier, press office, +412-1517-6717
thebrainforum@farner.ch

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Westlake Expands Global Chlorovinyls Manufacturing Capacity With Acquisition of PVC and VCM Plants in Wilhelmshaven, Germany15.6.2026 20:18:00 CEST | Press release

Westlake Corporation (NYSE: WLK) (“Westlake”) announced today that its German subsidiary, Westlake Vinnolit GmbH & Co. KG, has completed the previously-announced acquisition of a polyvinyl chloride and vinyl chloride monomer production site located in Wilhelmshaven, Germany (the “Wilhelmshaven plant”). The Wilhelmshaven plant, which was previously in insolvency administration, has the capacity to produce 380,000 metric tons of PVC per year. “This acquisition strengthens our Performance & Essential Materials business by expanding our global chlorovinyls manufacturing footprint and complements our existing chlorovinyl production facilities in Europe and North America,” said Jean-Marc Gilson, President and Chief Executive Officer of Westlake. “The Wilhelmshaven plant, which is located in Lower Saxony on Germany’s North Sea coast, benefits from advantageous logistical infrastructure, including a deep-water dock that enables efficient raw-materials supply. We look forward to welcoming the s

Onera Announces Integration of the Onera hPSG® Solution With Somnoware15.6.2026 19:35:00 CEST | Press release

Onera hPSG®, an end-to-end home polysomnography solution from Onera Health, is now integrated into Somnoware, enabling their customers to conduct Polysomnography tests (PSGs) in the patient's home while managing the entire workflow in Somnoware. Onera Health, a leader in transforming sleep medicine, announces that its end-to-end home polysomnography solution, the Onera hPSG® solution, now integrates with Somnoware by ResMed sleep lab management software. This integration enables clinicians to conduct Polysomnography tests (PSGs) where patients sleep most comfortably, in their own home, while managing the entire workflow in Somnoware. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615106079/en/ Onera hPSG®, an end-to-end home polysomnography solution from Onera Health, is now integrated into Somnoware, enabling their shared customers to conduct Polysomnography tests (PSGs) in the patient's home while managing the entire wo

Digital Cooperation Organization Launches Global Expert Community to Accelerate International Digital Cooperation15.6.2026 18:18:00 CEST | Press release

A global platform mobilizing expertise and collective action to advance shared digital priorities The Digital Cooperation Organization (DCO), the world's first standalone international organization dedicated to inclusive and sustainable digital economy growth, today announced the launch of the Global Expert Community (GEC) — a new platform designed to mobilize expertise and advance international collaboration in support of high-impact digital initiatives across DCO Member States and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615565781/en/ Digital Cooperation Organization Launches Global Expert Community to Accelerate International Digital Cooperation (Graphic: AETOSWire) The GEC reflects the DCO's continued commitment to turning digital cooperation into action by expanding access to specialized expertise and strengthening collaboration across sectors and borders. As digital transformation reshapes economies an

New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 115.6.2026 18:00:00 CEST | Press release

- Secondary and Exploratory Endpoint Results from Phase 3 Studies Presented at SLEEP 2026 Underscore Improvements with Oveporexton Across a Broad Range of Daytime and Nighttime Symptoms - Takeda is on Track to Bring the First and Only Orexin Agonist to People Living with Narcolepsy Type 1 with Regulatory Submissions Under Review Takeda (TSE:4502/NYSE:TAK)today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin receptor 2 (OX2R)-selective agonist, improved daily functioning as well as cognitive and sleep-related symptoms associated with narcolepsy type 1 (NT1).1,2,3 Oveporexton is designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. These data, along with previously disclosed Phase 3 results, demonstrated improvement across the broad disease spectrum, supporting the potential of oveporexton to redefine the standard of care for NT1.4 "Narcolepsy type 1 is a 24-hour disease drive

Boomi Named a Pioneer in June 2026 Gartner® Emerging Market Quadrant for No-Code Agent Builders15.6.2026 17:30:00 CEST | Press release

For Boomi, this recognition reinforces its vision and momentum in enterprise agentic AI Boomi, the data activation company for AI, today announced it has been recognized as aPioneer in the Gartner® Emerging Market Quadrant for No-Code Agent Builders (NCAB). Gartner defines the NCABs market as SaaS-delivered products that offer an integrated design and runtime environment to build, publish and manage AI-powered agents without using coding. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615413216/en/ Boomi Named a Pioneer in June 2026 Gartner® Emerging Market Quadrant for No-Code Agent Builders Boomi sees this recognition as a reflection of the company's rapid evolution from an integration and automation powerhouse to a full-scale agentic infrastructure platform, expanding Boomi’s role in the emerging agentic AI market. A New Chapter in Enterprise Agentic AI According to Gartner, vendors recognized as a Pioneer in this quad

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye